Cargando…

CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy

BACKGROUND: During the first years of the use of direct acting Hepatitis C antiviral drugs (DAAS), several studies reported a possible correlation between this new era of treatment and an increased risk of Hepatocellular carcinoma (HCC). Its development could possibly be favored by the changes in th...

Descripción completa

Detalles Bibliográficos
Autores principales: El Menshawy, Nadia, Hassan, Noha, Khariza, Mohamed, AlAshery, Hala, Baghat, Monir, Ashour, Rehab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Makerere Medical School 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398471/
https://www.ncbi.nlm.nih.gov/pubmed/37545943
http://dx.doi.org/10.4314/ahs.v23i1.22
_version_ 1785084066546057216
author El Menshawy, Nadia
Hassan, Noha
Khariza, Mohamed
AlAshery, Hala
Baghat, Monir
Ashour, Rehab
author_facet El Menshawy, Nadia
Hassan, Noha
Khariza, Mohamed
AlAshery, Hala
Baghat, Monir
Ashour, Rehab
author_sort El Menshawy, Nadia
collection PubMed
description BACKGROUND: During the first years of the use of direct acting Hepatitis C antiviral drugs (DAAS), several studies reported a possible correlation between this new era of treatment and an increased risk of Hepatocellular carcinoma (HCC). Its development could possibly be favored by the changes in the immunological milieu and the different cellular behavior after eradication of HCV infection with them. For this reason, this study aimed to address the immunological effect of DAAS SUBJECT & METHODS: Prospective paired -sample design, carried out on 90 naïve chronically infected HCV patients before and after receiving a combination therapy of sofosbuvir; at a dose of 400 mg once daily and daclatasvir; at a dose of 60 mg once daily for 12 weeks and follow up for one year. immunological tests including: total T cell count, T helper cell count, T cytotoxic cell count and natural killer cell count in peripheral blood through (CD3, CD3/CD4, CD3/CD8 and CD56 respectively) by Fluorochrome monoclonal antibodies labelled with specific dyes through Multiparameter, FACSCanto ™ II flow cytometer (Becton Dickinson, USA). RESULT: Concerning the immunological changes, total T cells (CD3+), Natural killer cells showed non-significant decrease at end of therapy while significant decrease in T helper cells (CD3+CD4+) T cytotoxic cells (CD3+CD8+) compared to pre-treatment value. Long follow up revealed 26.6% developed focal HCC, in more addition, multivariate analysis show CD4/CD8 ratio could be predictor as well as sex for early development of HCC after combined DAAS therapy. CONCLUSION: HCV treatment by DAAS produces significant decrease in T helper, T cytotoxic cells in CHC patients at the end of therapy. 26.6% developed focal HCC with independent CD4/CD8 predictor for burden malignancy. Further large extended population study is needed for clarify this concern.
format Online
Article
Text
id pubmed-10398471
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Makerere Medical School
record_format MEDLINE/PubMed
spelling pubmed-103984712023-08-04 CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy El Menshawy, Nadia Hassan, Noha Khariza, Mohamed AlAshery, Hala Baghat, Monir Ashour, Rehab Afr Health Sci Articles BACKGROUND: During the first years of the use of direct acting Hepatitis C antiviral drugs (DAAS), several studies reported a possible correlation between this new era of treatment and an increased risk of Hepatocellular carcinoma (HCC). Its development could possibly be favored by the changes in the immunological milieu and the different cellular behavior after eradication of HCV infection with them. For this reason, this study aimed to address the immunological effect of DAAS SUBJECT & METHODS: Prospective paired -sample design, carried out on 90 naïve chronically infected HCV patients before and after receiving a combination therapy of sofosbuvir; at a dose of 400 mg once daily and daclatasvir; at a dose of 60 mg once daily for 12 weeks and follow up for one year. immunological tests including: total T cell count, T helper cell count, T cytotoxic cell count and natural killer cell count in peripheral blood through (CD3, CD3/CD4, CD3/CD8 and CD56 respectively) by Fluorochrome monoclonal antibodies labelled with specific dyes through Multiparameter, FACSCanto ™ II flow cytometer (Becton Dickinson, USA). RESULT: Concerning the immunological changes, total T cells (CD3+), Natural killer cells showed non-significant decrease at end of therapy while significant decrease in T helper cells (CD3+CD4+) T cytotoxic cells (CD3+CD8+) compared to pre-treatment value. Long follow up revealed 26.6% developed focal HCC, in more addition, multivariate analysis show CD4/CD8 ratio could be predictor as well as sex for early development of HCC after combined DAAS therapy. CONCLUSION: HCV treatment by DAAS produces significant decrease in T helper, T cytotoxic cells in CHC patients at the end of therapy. 26.6% developed focal HCC with independent CD4/CD8 predictor for burden malignancy. Further large extended population study is needed for clarify this concern. Makerere Medical School 2023-03 /pmc/articles/PMC10398471/ /pubmed/37545943 http://dx.doi.org/10.4314/ahs.v23i1.22 Text en © 2023 Menshawy N El et al. https://creativecommons.org/licenses/by/4.0/Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
El Menshawy, Nadia
Hassan, Noha
Khariza, Mohamed
AlAshery, Hala
Baghat, Monir
Ashour, Rehab
CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy
title CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy
title_full CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy
title_fullStr CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy
title_full_unstemmed CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy
title_short CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy
title_sort cd4/cd8 ratio could be predictor of burden hepatocellular carcinoma in egyptian chronic hepatitis c after combined sofosbuvir and daclatasvir therapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398471/
https://www.ncbi.nlm.nih.gov/pubmed/37545943
http://dx.doi.org/10.4314/ahs.v23i1.22
work_keys_str_mv AT elmenshawynadia cd4cd8ratiocouldbepredictorofburdenhepatocellularcarcinomainegyptianchronichepatitiscaftercombinedsofosbuviranddaclatasvirtherapy
AT hassannoha cd4cd8ratiocouldbepredictorofburdenhepatocellularcarcinomainegyptianchronichepatitiscaftercombinedsofosbuviranddaclatasvirtherapy
AT kharizamohamed cd4cd8ratiocouldbepredictorofburdenhepatocellularcarcinomainegyptianchronichepatitiscaftercombinedsofosbuviranddaclatasvirtherapy
AT alasheryhala cd4cd8ratiocouldbepredictorofburdenhepatocellularcarcinomainegyptianchronichepatitiscaftercombinedsofosbuviranddaclatasvirtherapy
AT baghatmonir cd4cd8ratiocouldbepredictorofburdenhepatocellularcarcinomainegyptianchronichepatitiscaftercombinedsofosbuviranddaclatasvirtherapy
AT ashourrehab cd4cd8ratiocouldbepredictorofburdenhepatocellularcarcinomainegyptianchronichepatitiscaftercombinedsofosbuviranddaclatasvirtherapy